Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNS60 in ALS
NCT02525471Phase 1Completed
- Start
- Oct 2015
- Primary completion
- Jun 2017
- Modality
- Nanoparticles, Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RNS60 in amyotrophic lateral sclerosis (ALS). Primary endpoints: Safety as Measured by the Number of Participants Experiencing Adverse Events at 28 weeks, Tolerability to Complete the Entire 24 Week Study on Study Drug and 5 more. Started Oct 2015; status: completed.
02
Drugs
RNS60
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02525471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02525471.